ClinicalTrials.gg
CompletedNCT03709173Updated Oct 29, 2019

FuRST 2.0 Cognitive Pre-testing - Round 2

An observational study in Huntington Disease, sponsored by CHDI Foundation, Inc.. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-29.

Sponsored by CHDI Foundation, Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
52
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Huntington Disease by CHDI Foundation, Inc. — 2 open to participants now, 2 under way, none of them phase 3. Huntington Disease · CHDI Foundation, Inc..

Started
2019
the only one that year
Observational
7 of 11
1 open now
Registered
7th of 11
by date

Among the 11 studies in Huntington Disease by CHDI Foundation, Inc., this one is the only one that started in 2019, is one of 7 observational ones, and was the 7th registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

2 of the 11 studies in Huntington Disease by CHDI Foundation, Inc. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Huntington Disease by CHDI Foundation, Inc., or all of them as a file.
02

Study summary

The study is a single, cross-sectional cognitive interview of FuRST 2.0, functional rating scale, administered to forty Huntington's Disease Gene Expansion Carriers (HDGECs) and potentially, their companions (the companion's participation is optional in this study). The scale will be tested as a patient reported outcome (PRO) in that the information will come directly from the HDGEC participant or the HDGEC participant together with his/her companion through self-report. The purpose is to identify real or potential comprehension or usage problems with scale items, response options, instructions and disclaimer statement, which are all components of the FuRST 2.0 scale. Through a structured cognitive interview with the HDGEC participants or the HDGEC participants together with their companions, followed by qualitative analysis, the final phrasing of the individual scale items, response options, instructions and disclaimer statement for the scale will be generated. Depending on the results of this study, an additional round of cognitive pre-testing may be required in a separate study.

03

Conditions studied

  • Huntington Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

An HDGEC: Premanifest and early-manifest HDGEC who is also a participant in Enroll-HD and meets the protocol selection criteria for the HDGEC. HDGEC participants will be recruited from English speaking Enroll-HD sites.

A Companion: A person who, in his/her opinion, has sufficient interaction and knowledge of the HDGEC participant's capabilities and daily activities, is acceptable to the HDGEC participant and the site principal investigator (site PI) or site PI's designee and meets the protocol selection criteria for the companion. The companion's participation is optional in this study.

Eligibility criteria

Inclusion Criteria for Premanifest HDGECs:

  • Identified as an active participant in Enroll-HD (participants who have completed their last onsite Enroll-HD visit within approximately 15 months)
  • At least 18 years of age
  • Fluent in English and had his/her primary education in English
  • Able and willing to provide critical feedback (per site PI or site PI's designee discretion)
  • Willing and able to provide written
  • Cytosine, Adenine, Guanine (CAG) length ≥ 40
  • Disease burden score (DBS) ≥ 250
  • Diagnostic confidence level (DCL) ≤ 3

Inclusion Criteria for Early-manifest HDGECs:

  • Identified as an active participant in Enroll-HD (participants who have completed their last onsite Enroll-HD visit within approximately 15 months)
  • At least 18 years of age
  • Fluent in English and had his/her primary education in English
  • Able and willing to provide critical feedback (per site PI or site PI's designee discretion)
  • Willing and able to provide written informed consent
  • CAG length ≥ 36
  • DCL= 4
  • Total Functional Capacity (TFC) ≥11

Inclusion Criteria for a Companion of an HDGEC

  • At least 18 years of age
  • Fluent in English and had his/her primary education in English
  • In his/her opinion, has sufficient interaction and knowledge of the HDGEC participant's capabilities and daily activities
  • Is acceptable to the HDGEC participant and the site PI or site PI's designee
  • Willing and able to provide written informed consent

Exclusion Criteria for an HDGEC/a companion of HDGEC:

  • Significant cognitive or any other impairment sufficient to interfere with study associated tasks as judged by the site PI or the site PI's designee
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
52 participants (actual)
Patient registry
No

Groups and cohorts

  • Premanifest HDGEC participants

    Behavioral: FuRST 2.0

  • Early-manifest HDGEC participants

    Behavioral: FuRST 2.0

  • Companions of Premanifest HDGEC

    Behavioral: FuRST 2.0

  • Companions of Early-manifest

    Behavioral: FuRST 2.0

Interventions

  • BehavioralFuRST 2.0

    Round 2 of cognitive pre-testing for a new functional rating scale

06

What researchers measure

Primary outcomes

  1. Participant's comprehension of the FuRST 2.0 rating scale measured by qualitative analysis.

    The primary assessment will use qualitative analysis of the cognitive interview to determine the usability of the FuRST 2.0 scale in the HD population. Note: The instructions, items, response options and disclaimer statement are all part of the FuRST 2.0 scale.

    Time frame: 7 months

07

Study locations

4 sites
  • Rocky Mountain Movement Disorders Center, P.C.
    Englewood, Colorado 80113, United States
  • Hereditary Neurological Disease Centre, Inc.
    Wichita, Kansas 67226, United States
  • Columbia University
    New York, New York 10032, United States
  • Centre for Movement Disorders (Neuropharm Consulting)
    Toronto, Ontario M3B 2S7, Canada
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Oct 2019, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2018
First posted
Oct 17, 2018
StartActual
Aug 2, 2019
Primary completionActual
Oct 25, 2019
CompletionActual
Oct 25, 2019
Last update
Oct 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03709173
Lead sponsor
CHDI Foundation, Inc.
Collaborators
Dr. Glenn T. Stebbins (Rush University Medical Center ), Dr. Nancy LaPelle
Responsible party
Sponsor
First posted
Oct 17, 2018
Start date
Aug 2, 2019
Primary completion
Oct 25, 2019
Completion
Oct 25, 2019
Last update
Oct 29, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion